Nexalin Technology, Inc. (NXL) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Nexalin Technology, Inc. is a medical device company developing neurostimulation products (Gen-1, Gen-2 SYNC, and Gen-3 HALO) to treat mental health conditions such as anxiety, insomnia, depression, and Alzheimer's disease. The company is classified as a Smaller Reporting Company and an Emerging Growth Company.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Revenue | $14,950 | $41,015 |
| Gross Profit | $13,133 | $27,457 |
| Gross Margin | 88% | 67% |
| Net Loss | $(2,096,837) | $(1,988,337) |
| Loss Per Share (Basic/Diluted) | $(0.11) | $(0.15) |
| Cash & Cash Equivalents | $1,207,895 | $622,029 |
| Short-term Investments | $1,500,590 | $3,068,429 |
| Total Current Assets | $3,290,154 | $4,299,270 |
| Total Current Liabilities | $808,364 | $887,333 |
| Working Capital | $2,481,790 | $3,411,937 |
| Accumulated Deficit | $(94,964,249) | $(88,633,568) |
Material Changes vs. Prior Period
- Revenue Decline: Net revenue decreased by 64% to $14,950, primarily due to lower equipment sales to international customers. Gross margin improved to 88% due to a higher mix of licensing fees.
- Operating Expenses: Total operating expenses increased 5% to $2.13 million. Increases in professional fees (+35%) and salaries/benefits (+49%) were partially offset by decreases in SG&A (-15%) and R&D (-15%).
- Cash Flow: Net cash used in operating activities increased to $1.71 million. Net cash provided by investing activities was $1.51 million, driven by the sale of short-term investments. Financing activities provided $756,000 via the ATM program.
- Capital Structure: The company issued 1,395,300 shares under its At-The-Market (ATM) program, raising net proceeds of approximately $756,000.
Outlook, Risks, and Management Commentary
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern for the next 12 months. The company has an accumulated deficit of ~$95 million and expects to continue incurring losses. Additional capital will be required to fund clinical trials and operations.
- Nasdaq Compliance: The company received a deficiency letter on January 21, 2026, for failing to maintain the $1.00 minimum bid price. It has until July 20, 2026, to regain compliance.
- Regulatory Progress: The FDA formally accepted the Q-Submission for the Gen-2 SYNC system for Alzheimer's/dementia in October 2025. In April 2026, the company entered a Scope of Work with Lindus Health for a pivotal clinical trial of the Gen-3 HALO device for insomnia, with fees of approximately $945,000.
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting, specifically regarding segregation of duties and IT access controls.
Investor Verification Checklist
- Cash Runway: Verify if current cash ($1.2M) and short-term investments ($1.5M) are sufficient to cover the $945,000 clinical trial commitment and ongoing operating losses without immediate dilution.
- ATM Capacity: Confirm the remaining capacity under the ATM program (approx. $4.27M aggregate offering price) and the current market price relative to the $1.00 Nasdaq minimum bid requirement.
- Revenue Sustainability: Assess the volatility of international equipment sales and the timeline for potential U.S. revenue generation from Gen-2 and Gen-3 devices.
- Remediation Plan: Review the specific steps and timeline management has outlined to remediate the material weaknesses in internal controls.